Potential benefits of screening do not outweigh potential harms in asymptomatic adults.
Pancreatic ductal adenocarcinoma is characterized by a tumor microenvironment that inhibits immune signaling.
Boston Biomedical has announced that the CanStem111P study investigating napabucasin in patients with metastatic pancreatic cancer will be discontinued due to futility.
Researchers find that total neoadjuvant therapy has a significant impact on survival for patients with borderline resectable or locally advanced PDAC.
Using data from the CPS-II, researchers determined a link between higher BMI in adults younger than 50 years and risk of pancreatic cancer.